This is particularly relevant in a GSNOR-deficient model of hepatocellular carcinoma (HCC) where GSNOR loss increases SDH activity and, in turn, confers high sensitivity to SDH-targeting drugs (Rizza et al., 2016). The gene discussed is ADH5; the disease is hepatocellular carcinoma.